BGPT: Create Graphs: SARS-CoV-2 Mutation Effect Sizes

Explore by Goal

Quick Analysis Plan Copied

The best plan is to graph only the mutation effect sizes actually reported in the supplied sources — D614G infectivity enhancement, nsp1 Δ82-85/Δ83-86 interferon-inhibition loss, comparative mutation rates, and Omicron spike mutation counts — with Plotly, flagging which values are qualitative versus quantitative.

Long Analysis Plan

Evidence-Backed Graphing Plan: SARS-CoV-2 Mutation Effect Sizes

Only mutations with reported quantitative or clearly directional effects from the supplied sources should be graphed. The defensible set is: D614G spike (higher infectious titers in pseudovirus assays, enhanced replication in human airway tissues and hamster upper respiratory tracts) ; nsp1 Δ82-85 and Δ83-86 (significantly reduced interferon-signaling inhibition, no virulence effect in hamsters) ; mutation rates (SARS-CoV-2 1.3×10⁻⁶±0.2×10⁻⁶, Influenza 2.0×10⁻⁶±0.6×10⁻⁶, Rhinovirus 3.4×10⁻⁴ per base per infection cycle) and Omicron spike mutation counts (37 total, 15 in RBD) .

Recommended additional panels: (1) A diverging effect-size panel for D614G and nsp1 deletions using standardized annotations (direction of effect, assay system, confidence tier), since no common quantitative unit exists across them — do not invent normalized values; (2) a grouped bar chart of Omicron spike mutation counts (total vs RBD) annotated with the ACE2 salt-bridge/hydrogen-bond mechanism ; (3) optionally a transmissibility comparison (R0: SARS-CoV-2 4.18, Influenza 1.68, Rhinovirus 1.88) contextualized as outcome correlates, not mutation effects per se.

Critical caveats to annotate on every figure: D614G effects come from hamsters, Vero E6, Calu-3, and primary airway tissues with non-randomized animal experiments and no blinding; nsp1 findings use a WA1 backbone that may not generalize to Omicron; the mutation-rate review is a non-systematic student review citing preprints, so rates should be cross-checked before publication use. The Bioinformatics Wizard code below implements this pipeline reproducibly.

Feedback:

Updated: October 05, 2026

Top Data Sources Export MCP

1. This study investigates the impact of the D614G mutation in the spike protein of SARS-CoV-2, demonstrating that it enhances viral replication and infectivity in human airway tissues and hamsters, with implications for transmission and vaccine efficacy. [2020]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

2. The authors report a 2.4 Å crystal structure of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex with sinefungin, revealing active sites highly conserved among coronaviruses but not flaviviruses and providing a basis for inhibitor design. [2020]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. In a population-based cohort, the study examines the influence of the SARS-CoV-2 pandemic and SARS-CoV-2 infection on musculoskeletal health, finding that pandemic-related lifestyle changes modestly affect body composition while infection itself is not linked to major deterioration in muscle mass or function. [2025]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

4. This study identifies bats as the most likely host reservoir for SARS-CoV-2 and estimates that the spillover to humans occurred between 2007 and 2019, based on phylogenetic and Bayesian evolutionary analyses of coronavirus genomes. [2023]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

5. This study investigates the immune responses in a case of SARS-CoV-2 and HIV co-infection, revealing significant immune activation and dysregulation that may lead to poor clinical outcomes in HIV-infected individuals. [2023]

7QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

The supplied evidence contains no single unified effect-size metric; mixing qualitative mutation effects into one numeric axis fabricates data. The honest graphing strategy separates assay systems (pseudovirus, hamster, structural counts) and reports uncertainty tiers visually.

Keep Exploring

How do deep-mutational-scanning-derived effect sizes for SARS-CoV-2 spike residues compare with the phenotype effects observed in recombinant virus competition assays like the D614G study?

What would a unified effect-size framework across structural, replication, and immune-evasion mutation phenotypes for SARS-CoV-2 need to account for statistically?

Analysis Wizard

Building publication-grade Plotly visualizations of reported SARS-CoV-2 mutation effect sizes, mutation rates, and spike mutation counts, with explicit uncertainty and evidence-strength annotations for each panel.

Hypothesis Graveyard

D614G increases disease severity: pseudovirus and hamster data showed higher infectivity and viral loads without a clear severity link, so this explanation was dropped.

Proofreading alone determines transmissibility: rhinovirus has a far higher mutation rate yet a lower R0 (1.88 vs 4.18), so fidelity cannot be the dominant transmissibility driver.

Potential Experiments

Run head-to-head competition assays (D614 vs G614) with matched Omicron-backbone recombinant viruses in primary human airway epithelia with blinded endpoint quantification to remove the WA1-backbone and non-blinding limitations of prior work.

Quantify interferon-inhibition effect sizes of nsp1 Δ82-85 across D614, Delta, and Omicron backbones with identical luciferase reporter assays, yielding directly comparable continuous effect sizes suitable for meta-analysis.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data likely over-represents mechanistic variant-effect literature, which could bias me toward treating pseudovirus infectivity effects as directly generalizable to human transmissibility.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Graphs Built From Reported Results

Turn exact figures reported in papers into graphs, each point traced to its source.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Evidence-Backed Graphing Plan: SARS-CoV-2 Mutation Effect Sizes

Top Data Sources Export MCP

1. This study investigates the impact of the D614G mutation in the spike protein of SARS-CoV-2, demonstrating that it enhances viral replication and infectivity in human airway tissues and hamsters, with implications for transmission and vaccine efficacy. [2020]

2. The authors report a 2.4 Å crystal structure of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex with sinefungin, revealing active sites highly conserved among coronaviruses but not flaviviruses and providing a basis for inhibitor design. [2020]

4. This study identifies bats as the most likely host reservoir for SARS-CoV-2 and estimates that the spillover to humans occurred between 2007 and 2019, based on phylogenetic and Bayesian evolutionary analyses of coronavirus genomes. [2023]

5. This study investigates the immune responses in a case of SARS-CoV-2 and HIV co-infection, revealing significant immune activation and dysregulation that may lead to poor clinical outcomes in HIV-infected individuals. [2023]

6. This study investigates the impact of naturally occurring N-terminal mutations in the SARS-CoV-2 nsp1 protein on innate immune modulation and virus virulence, revealing that these mutations impair immune inhibition without affecting viral replication in a hamster model. [2024]

7. This paper reviews how SARS-CoV-2's proofreading system (nsp14/nsp10 ExoN) limits spike mutations and examines how this fidelity impacts viral infectivity, including discussion of D614G and Omicron mutations and their implications for transmissibility and vaccine evasion. [2023]

10. This study identifies potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection, demonstrating their efficacy in neutralizing various SARS-CoV-2 variants and related coronaviruses. [2025]

11. This paper presents a correction to previously published research on the clinical testing of SARS-CoV-2 swab samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP) and two extraction-free RT-LAMP assays for the detection of SARS-CoV-2. [2023]

12. This study investigates the impact of SARS-CoV-2 mRNA vaccination and infection on leukocyte counts in solid organ transplant recipients, finding no association between vaccination and decreased leukocyte counts, while infection significantly increased the risk of leukopenia. [2025]

Ask a Follow-Up

Key Insight

The supplied evidence contains no single unified effect-size metric; mixing qualitative mutation effects into one numeric axis fabricates data. The honest graphing strategy separates assay systems (pseudovirus, hamster, structural counts) and reports uncertainty tiers visually.

Keep Exploring

How do deep-mutational-scanning-derived effect sizes for SARS-CoV-2 spike residues compare with the phenotype effects observed in recombinant virus competition assays like the D614G study?

What would a unified effect-size framework across structural, replication, and immune-evasion mutation phenotypes for SARS-CoV-2 need to account for statistically?

Analysis Wizard

Building publication-grade Plotly visualizations of reported SARS-CoV-2 mutation effect sizes, mutation rates, and spike mutation counts, with explicit uncertainty and evidence-strength annotations for each panel.

Hypothesis Graveyard

D614G increases disease severity: pseudovirus and hamster data showed higher infectivity and viral loads without a clear severity link, so this explanation was dropped.

Proofreading alone determines transmissibility: rhinovirus has a far higher mutation rate yet a lower R0 (1.88 vs 4.18), so fidelity cannot be the dominant transmissibility driver.

Potential Experiments

Run head-to-head competition assays (D614 vs G614) with matched Omicron-backbone recombinant viruses in primary human airway epithelia with blinded endpoint quantification to remove the WA1-backbone and non-blinding limitations of prior work.

Quantify interferon-inhibition effect sizes of nsp1 Δ82-85 across D614, Delta, and Omicron backbones with identical luciferase reporter assays, yielding directly comparable continuous effect sizes suitable for meta-analysis.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data likely over-represents mechanistic variant-effect literature, which could bias me toward treating pseudovirus infectivity effects as directly generalizable to human transmissibility.

Stay current without chasing every paper.

My BGPT

Trending

Graphs Built From Reported Results

Turn exact figures reported in papers into graphs, each point traced to its source.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Evidence-Backed Graphing Plan: SARS-CoV-2 Mutation Effect Sizes

Top Data Sources ExportMCP

1. This study investigates the impact of the D614G mutation in the spike protein of SARS-CoV-2, demonstrating that it enhances viral replication and infectivity in human airway tissues and hamsters, with implications for transmission and vaccine efficacy. [2020]

2. The authors report a 2.4 Å crystal structure of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex with sinefungin, revealing active sites highly conserved among coronaviruses but not flaviviruses and providing a basis for inhibitor design. [2020]

4. This study identifies bats as the most likely host reservoir for SARS-CoV-2 and estimates that the spillover to humans occurred between 2007 and 2019, based on phylogenetic and Bayesian evolutionary analyses of coronavirus genomes. [2023]

5. This study investigates the immune responses in a case of SARS-CoV-2 and HIV co-infection, revealing significant immune activation and dysregulation that may lead to poor clinical outcomes in HIV-infected individuals. [2023]

6. This study investigates the impact of naturally occurring N-terminal mutations in the SARS-CoV-2 nsp1 protein on innate immune modulation and virus virulence, revealing that these mutations impair immune inhibition without affecting viral replication in a hamster model. [2024]

7. This paper reviews how SARS-CoV-2's proofreading system (nsp14/nsp10 ExoN) limits spike mutations and examines how this fidelity impacts viral infectivity, including discussion of D614G and Omicron mutations and their implications for transmissibility and vaccine evasion. [2023]

10. This study identifies potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection, demonstrating their efficacy in neutralizing various SARS-CoV-2 variants and related coronaviruses. [2025]

11. This paper presents a correction to previously published research on the clinical testing of SARS-CoV-2 swab samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP) and two extraction-free RT-LAMP assays for the detection of SARS-CoV-2. [2023]

12. This study investigates the impact of SARS-CoV-2 mRNA vaccination and infection on leukocyte counts in solid organ transplant recipients, finding no association between vaccination and decreased leukocyte counts, while infection significantly increased the risk of leukopenia. [2025]

Ask a Follow-Up

Key Insight

The supplied evidence contains no single unified effect-size metric; mixing qualitative mutation effects into one numeric axis fabricates data. The honest graphing strategy separates assay systems (pseudovirus, hamster, structural counts) and reports uncertainty tiers visually.

Keep Exploring

How do deep-mutational-scanning-derived effect sizes for SARS-CoV-2 spike residues compare with the phenotype effects observed in recombinant virus competition assays like the D614G study?

What would a unified effect-size framework across structural, replication, and immune-evasion mutation phenotypes for SARS-CoV-2 need to account for statistically?

Analysis Wizard

Building publication-grade Plotly visualizations of reported SARS-CoV-2 mutation effect sizes, mutation rates, and spike mutation counts, with explicit uncertainty and evidence-strength annotations for each panel.

Hypothesis Graveyard

D614G increases disease severity: pseudovirus and hamster data showed higher infectivity and viral loads without a clear severity link, so this explanation was dropped.

Proofreading alone determines transmissibility: rhinovirus has a far higher mutation rate yet a lower R0 (1.88 vs 4.18), so fidelity cannot be the dominant transmissibility driver.

Potential Experiments

Run head-to-head competition assays (D614 vs G614) with matched Omicron-backbone recombinant viruses in primary human airway epithelia with blinded endpoint quantification to remove the WA1-backbone and non-blinding limitations of prior work.

Quantify interferon-inhibition effect sizes of nsp1 Δ82-85 across D614, Delta, and Omicron backbones with identical luciferase reporter assays, yielding directly comparable continuous effect sizes suitable for meta-analysis.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data likely over-represents mechanistic variant-effect literature, which could bias me toward treating pseudovirus infectivity effects as directly generalizable to human transmissibility.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP